Hypothesis

Clonal hematopoietic mosaic chromosomal alterations (mCAs) release extracellular vesicles (EVs) that carry altered cargo (DNA fragments, miRNAs, and proteins) which remodel lung stromal fibroblasts into a pro‑tumorigenic phenotype. This fibroblast reprogramming secretes TGF‑β, IL‑6, and CXCL12, establishing a pre‑metastatic niche that accelerates lung carcinogenesis. Germline copy‑number variants (CNVs) in DNA‑damage response genes such as ATM modulate the quantity and oncogenic potency of these EVs, thereby linking inherited risk, age‑related mCAs, and solid‑tumor onset.

Background

• mCAs increase with age and confer a 10‑fold higher risk of hematologic cancer, with expanded autosomal mCAs showing hazard ratios >121 for CLL【PMC10435278】.
• Autosomal mCAs in leukocytes raise lung cancer risk by 33 %; copy‑neutral LOH drives 44‑54 % risk for specific subtypes【PMC10435278】.
• Lung cancer patients acquire mCAs 5‑10 years earlier than controls, indicating accelerated biological aging precedes tumor formation【PMC10435278】.
• Co‑occurrence of CHIP driver mutations and CNAs is common; JAK2 with 9pUPD yields OR = 231, TP53 with 17pUPD OR = 88【ash.confex.com/ash/2020/webprogram/Paper142173.html】.
• Hematopoietic aging promotes emergency myelopoiesis, accumulating immunosuppressive myeloid progenitors in lung tumors【synthetic_research_questions_feedback_2.md】.
• Germline variation at 24 loci influences CHIP susceptibility, including ATM, LY75, CD164, GSDMC, which also associate with mosaic loss of chromosome Y【PMC9713173】.
• Ancestry differences show elevated mosaic X alterations in African and Hispanic populations【PMC10632132】.
• Nearly half of highly penetrant Mendelian cancer genes appear as rare CNVs, though they explain <5 % of familial cancers【ovid.com/journals/fonc/fulltext/10.2217/fon.12.34~germline-copy-number-variations-and-cancer-predisposition】.
• Combined mCAs, CHIP mutations, and germline CNVs modulate hematologic and cardiovascular mortality【pubmed.ncbi.nlm.nih.gov/34239136/】.

Proposed Mechanism

1. EV Release – Hematopoietic clones bearing mCAs (e.g., 9pUPD, 17pUPD) shed EVs enriched for mutant DNA fragments, oncogenic miRNAs (miR‑155, miR‑21), and altered surface markers (CD45⁺, CD34⁺).
2. EV Uptake by Lung Fibroblasts – Circulating EVs home to the lung via CXCR4‑CXCL12 chemotaxis and are internalized by resident fibroblasts through endocytosis.
3. Fibroblast Reprogramming – EV‑delivered cargo activates STAT3 and SMAD pathways, converting fibroblasts to a cancer‑associated fibroblast (CAF) state characterized by α‑SMA⁺, FAP⁺, and heightened secretion of TGF‑β, IL‑6, CXCL12, and matrix‑remodeling enzymes (MMP2, MMP9).
4. Niche Formation – The secretory CAF phenotype creates a pro‑inflammatory, immunosuppressive matrix that recruits and shields early transformed epithelial cells, facilitating clonal expansion.
5. Germline Modulation – Individuals carrying germline CNVs that increase ATM dosage or alter its regulation produce EVs with higher DNA‑damage signaling content, amplifying fibroblast activation. Conversely, ATM‑loss CNVs diminish EV oncogenicity.

Testable Predictions

• Prediction 1: Plasma EVs from older donors with detectable mCAs will induce CAF markers in primary human lung fibroblasts more efficiently than EVs from age‑matched donors without mCAs (in vitro).
• Prediction 2: Lung fibroblasts exposed to mCA‑positive EVs will show increased secretion of TGF‑β and IL‑6, measurable by ELISA, and this secretion will be attenuated by ATM‑targeting siRNA in the fibroblast compartment.
• Prediction 3: Mice reconstituted with hematopoietic stem cells engineered to carry a common mCA (e.g., trisomy 12) will develop more lung metastases after carcinogen exposure than control chimeras; lung fibroblasts from these mice will display a CAF transcriptome.
• Prediction 4: Human lung cancer patients with germline ATM‑copy‑number gains will have higher circulating levels of mCA‑associated EVs and poorer survival compared with patients lacking the CNV, after adjusting for mCA burden.

Experimental Approach

• EV Isolation & Characterization: Collect plasma from participants in the cohort stratified by mCA status (detected vs. not) and germline CNV profile. Isolate EVs via ultracentrifugation or size‑exclusion chromatography; quantify particle number, size, and cargo (ddPCR for mCA‑specific DNA, small‑RNA sequencing for miRNAs).
• Fibroblast Assays: Culture primary human lung fibroblasts; treat with EVs (normalized by particle count). Assess CAF marker expression (α‑SMA, FAP) by flow cytometry and qPCR; measure cytokine secretion (TGF‑β, IL‑6, CXCL12) via multiplex ELISA.
• In Vivo Model: Generate competitive bone‑marrow chimeras in irradiated mice using HSCs transduced with a CRISPR‑based system to induce a recurrent mCA (e.g., gain of chromosome 8). After recovery, expose mice to urethane or NSCLC cell line injection; monitor tumor burden by bioluminescence and histology.
• Clinical Correlation: In the lung cancer subset, genotype germline CNVs (using SNP array or low‑coverage WGS). Correlate CNV burden with plasma EV mCA‑allele frequency and overall survival using Cox proportional hazards models.

If EV‑mediated fibroblast reprogramming is confirmed, it would mechanistically explain why mCAs appear years before lung cancer diagnosis and how germline variation shapes cancer risk beyond direct mutagenesis. Disproving the hypothesis would require showing that mCA‑positive EVs do not alter fibroblast function or that germline CNVs do not modulate EV oncogenic activity, redirecting focus to alternative pathways such as soluble cytokine secretion or direct mutagenic effects of mCA‑bearing cells in the lung microenvironment.